Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leriglitazone versus placebo in adult men with cerebral adrenoleukodystrophy
2024-515104-39-00Phase 3Authorised
- Sponsor
- Minoryx Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in cerebral adrenoleukodystrophy (CALD) comparing Leriglitazone with Placebo (2 arms). Primary endpoint: Time to death or becoming bedridden with permanent ventilatory support. Planned start Oct 2024; status: authorised.
02
Drugs
leriglitazone
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on 2024-515104-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515104-39-00.